Shionogi & Co., Ltd., commonly known as Shionogi, is a prominent pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, Shionogi has established itself as a leader in the pharmaceutical industry, focusing on research and development in areas such as infectious diseases, pain management, and central nervous system disorders. With a strong presence in Japan and expanding operations in North America and Europe, Shionogi is renowned for its innovative core products, including antiviral treatments and analgesics. The company’s commitment to advancing healthcare solutions has led to significant milestones, including the development of groundbreaking therapies that address unmet medical needs. Shionogi's dedication to quality and innovation has positioned it as a key player in the global pharmaceutical market, earning recognition for its contributions to public health and patient care.
How does Shionogi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Shionogi's score of 62 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Shionogi & Co., Ltd. reported total carbon emissions of approximately 214,942,000 kg CO2e. This includes Scope 1 emissions of about 40,373,000 kg CO2e, Scope 2 emissions of approximately 31,650,000 kg CO2e, and significant Scope 3 emissions totalling around 142,919,000 kg CO2e. The company has set ambitious targets to reduce its carbon footprint, aiming for a 46.2% reduction in absolute Scope 1 and 2 emissions by 2030, based on 2019 levels. Additionally, Shionogi is committed to reducing Scope 3 emissions from purchased goods and services by 20% by the same year. Shionogi's long-term goal is to achieve net-zero emissions across all scopes by 2050. The company has also pledged to reduce Scope 1 emissions to near zero by 2025 and Scope 2 emissions to near zero by the same timeframe. These commitments align with the Science Based Targets initiative (SBTi) and reflect Shionogi's dedication to addressing climate change within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,456,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 46,681,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 196,761,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Shionogi's Scope 3 emissions, which increased by 1% last year and decreased by approximately 27% since 2017, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 66% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shionogi has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Shionogi's sustainability data and climate commitments